Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up - Rugo, HS; Finn, RS; Diéras, V (Breast Cancer Res Treat, 2019)